Overview

A Phase 1, Open-Label, Single-Dose, Pharmacokinetic and Safety Study of E7080 (24 mg) Administered to Subjects With Mild, Moderate, and Severe Renal Impairment and to Healthy Subjects

Status:
Completed

Trial end date:
2012-10-01

Target enrollment:

Participant gender:

Summary

The purpose of this multicenter, open-label, non-randomized, single, oral dose, sequential-cohort study was to determine pharmacokinetics and safety of lenvatinib (24 mg) administered to healthy subjects and to subjects with renal impairment.

Phase:

Phase 1

Details

Lead Sponsor:

Eisai Inc.

Treatments:

Lenvatinib